

India's consumer prices (CPI Inflation) rose to 3.36% YoY in August 2017 from 2.36% YoY in July 2017 led by uptick in food as well as core inflation. Food inflation increased to 2.0% YoY in August 2017 from 0.4% YoY in July 2017. The upside in food inflation was driven by vegetable prices yet again due to rise in prices of certain specific items such as tomatoes, cabbages and onions. The core-CPI inflation inched up to 4.5% YoY in August 2017 from 4.0% YoY in July 2017. The Wholesale Price Index (WPI) went up from 1.90% YoY in July 2017 to 3.20% YoY in August 2017 driven by rise in food and fuel inflation.

India's exports grew 10.29% in Aug 2017 to USD 23.82 billion. Imports rose 21.02% to USD 35.46 billion. The overall trade deficit for Apr-Aug 2017 is estimated at USD 39.87 billion.

The US Federal Reserve left interest rates unchanged but signalled one more increase in 2017 and set an October start for shrinking holdings of US Treasury bonds and mortgage-backed securities acquired in the years after the 2008 financial crisis. It forecast only two increases in 2019 and one in 2020.


India's current account deficit stood at a four year high of USD 14.3 bn (2.4% of GDP) in Q1FY18 from USD 3.5 bn (0.6% of GDP) in Q4FY17. On a QoQ basis, higher CAD was due to wider trade deficit (USD 41.2 bn in Q1FY18 vs. USD 29.7 bn in Q4FY17), Lower exports (tracking weak global demand & stronger INR), high overall imports (muted domestic production hints at some import substitution), higher gold imports and high global commodity prices (implied a wider trade deficit). Despite the increase in CAD,

the surplus under the balance of payment increased to USD 11.4 bn in Q1 FY18 from USD 7.3 bn in Q4 FY18 on the back of robust capital inflows


Outlook

With most of the disinflation behind us, the inflation trajectory remains northward hereon. A consumption led growth revival, high revenue spending seen so far, oil prices stabilizing and much of the appreciation in INR playing out, structural upticks to inflation could emerge. Given the uptick in inflationary expectations and hardening of core inflation, we believe there remains limited scope for further easing from the central bank for rest of the calendar year.


Sector Allocation



Maturity Allocation



Duration Allocation



	USD Institutional	USD RDR	USD Retail	USD Super Institutional	SGD Retail	EUR Institutional
ISIN	IE00B87MVW30	IE00B8HFTC82	IE00B813ZW08	IE00BD3WYC32	IE00BDH6RX35	IE00BDH6RW28
Bloomberg code	BBG003LYY2M9	BBG003LYY2R4	BBG003LYY301	BBG00FFBC4K1	BBG00FFBCIF3	BBG00GSNSVH6

This report has been supplied solely for use by the person to whom it is made available. The Company makes no representation with regard to the completeness and accuracy of the data or information contained herein, and it accepts no responsibility and disclaims all liability for loss or damage whatsoever suffered or incurred by any other person resulting from the use of, or reliance upon, the data or information contained herein. Certain information in this document has been provided by third-party sources and, although believed to be reliable, it has not been independently verified and its accuracy or completeness cannot be guaranteed. This document does not constitute an Offer for share/units and is neither a recommendation nor statement of opinion or an advertisement. The content of the statement are for illustration/ information & discussion purpose only without regard to the specific objectives, financial situation and particular needs of any specific person who may receive this statement, such person may wish to seek advice from a financial adviser before committing to invest in any of the Fund. If such person chooses not to do so, he should consider carefully whether the investment is suitable for him. Past performance mentioned herein is/are not necessarily indicative of future performance. Investments in the Fund(s) are subject to risk, including possible loss of the principal amount invested. Investors must read the prospectus before making any investment decision. This document does not contain material information about the Fund, including important disclosures and risk factors associated with the investment in the Fund.

Germany

The Bundesanstalt für Finanzdienstleistungsaufsicht (Federal Agency for Financial Services Supervision) has been notified pursuant to Sec. 132 Investmentgesetz (Investment Act) of the intention to publicly distribute Shares of the Fund in the Federal Republic of Germany. The legal documents can be obtained in German, free of charge, from the information agent. The Information Agent in Germany is BHF-BANK Aktiengesellschaft, Bockenheimer Landstrasse 10, 60323 Frankfurt am Main.

Guernsey

UTI International Ltd, Guernsey (UTI IL) is a regulated entity in Guernsey, governed by Guernsey law, and is under the Protection of Investors (Bailiwick of Guernsey) Law 1987.

Hong Kong

The distribution of this document/ the prospectus / KIID or any marketing material ("this material") of the Fund ("the Fund"), may only be made in Hong Kong in circumstances that do not constitute an issue, invitation or offer to the public under the Hong Kong Securities and Futures Ordinance ("Securities and Futures Ordinance"). This material is confidential to you. The contents of this material have not been reviewed by any regulatory authority in Hong Kong. You are advised to exercise caution in relation to the offering of the shares described in this material. If you are in any doubt about any of the contents of this material, you should obtain independent professional advice. The Fund has not been authorized by the Securities and Futures Commission in Hong Kong pursuant to Section 104 of the Securities and Futures Ordinance nor has the offering memorandum been registered by the Registrar of Companies in Hong Kong pursuant to the Hong Kong Companies Ordinance ("Companies Ordinance"). Accordingly, unless permitted by the Securities and Futures Ordinance no person may issue or have in its possession for issue in Hong Kong this material or any other invitation, advertisement or document relating to the Participating Shares interests in the Fund to anyone other than (1) to professional investors within the meaning of the Securities and Futures Ordinance and any rules made there under, (2) to persons and in circumstances which do not constitute an invitation or offer to the public within the meaning of the Securities and Futures Ordinance or the Companies Ordinance, or (3) otherwise pursuant to, and in accordance with the conditions of, any other applicable provisions of the Securities and Futures Ordinance and the Companies Ordinance

India

The Fund has not been and will not be registered as a prospectus with the Registrar of Companies in India and that the Shares of the Fund has not been offered or sold in India and that it should not be offered or sold in India. This document or the Prospectus or any other offering document or material relating to the Shares of the Fund, should not be circulated or distributed this document, directly or indirectly, to the public or any members of the public in India.

Ireland

The Fund is an open-ended investment company with variable capital incorporated with limited liability in Ireland under the Companies Acts, 1963 to 2012 with registration number 516063 and established as an undertaking for collective investment in transferable securities pursuant to the European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations, 2011). The Fund is both authorised and supervised by the Central Bank. Authorisation of the Fund by the Central Bank shall not constitute a warranty as to the performance of the Fund and the Central Bank shall not be liable for the performance or default of the Fund. The authorisation of the Fund is not an endorsement or guarantee of the Fund by the Central Bank and the Central Bank is not responsible for the contents of the Prospectus of the Fund.

Singapore

The Fund is a recognised scheme under the Securities and Futures Act, Chapter 289 of Singapore ("SFA"). A copy of the Singapore Prospectus has been lodged with and registered by the Monetary Authority of Singapore ("MAS"). Investors from Singapore

must read the Singapore prospectus and the product highlights sheet before making any investment decision. The MAS assumes no responsibility for the contents of the Singapore Prospectus. Registration of the Singapore Prospectus by the MAS does not imply that the SFA or any other legal or regulatory requirements have been complied with. The MAS has not, in any way, considered the investment merits of the Company. The distribution of this Singapore Prospectus and the offering or sale of the Shares in the Company in some jurisdictions may be restricted or prohibited. Persons who have possession of the Singapore Prospectus of the Fund must inform themselves about and observe such restrictions or prohibitions.

Spain

The UTI Indian Fixed Income Fund Plc, SICAV is duly registered in the CNMV official registry of foreign collective investment institutions as authorised to be marketed to the public in Spain with number 1566. In Spain, any investment must be made through the authorised distributors and on the basis of the information contained in the mandatory documentation that must be received from the authorised distributor of the SICAV prior to any subscription, or that may be obtained from the CNMV registries.

Switzerland

The Company is authorized for public distribution in and from Switzerland by the Swiss Financial Market Supervisory Authority ("FINMA"). Investors from Switzerland should read the Consolidated Prospectus for use solely in Switzerland. The representative and paying agent in Switzerland is RBC Investor Services Bank S.A., Esch-sur-Alzette, Zurich Branch, Badenerstrasse 567, P.O. Box P.O. Box 1292, 8048 Zurich (the "Representative"). In Switzerland, the funds prospectus, Key Investor Information Document (KIID), the articles of association, the annual and semi-annual reports may be obtained free of charge from the Representative. In respect of the units distributed in and from Switzerland, the places of performance and jurisdiction is the registered office of the Representative."

U.K

Any financial promotion contained herein, as defined by UK regulations, has been approved by UTI International Limited (FCA no:183361); a firm authorised and regulated by the Financial Conduct Authority ("FCA"). U.K The Fund mentioned herein has been recognised by the FCA pursuant to section 264 of the FSMA. Facilities Agent is UTI International Limited, 45 King William Street London EC4R 9AN United Kingdom. Copies of the legal documents can be obtained in English, free of charge, from the Facilities Agent at 45 King William Street London EC4R 9AN, United Kingdom. The promotion of the Company in the United Kingdom can be carried out by persons authorized to carry on investment business in the United Kingdom under the FSMA and is not subject to the restrictions on promotion contained in section 238 of the FSMA. The FCA has not approved and takes no responsibility for the contents of the Prospectus or the UK Country Supplement or for any document referred to in them, nor for the financial soundness of the Fund or for the correctness of any statements made or expressed in the Prospectus or the UK Country Supplement or any document referred to in them.

United States of America

The Shares have not been nor will they be registered under the U.S. Securities Act of 1933, as amended (the "1933 Act"), or registered or qualified under the securities laws of any of the states of the United States. The Shares may not be offered, sold or delivered directly or indirectly in the United States or to or for the account or benefit of any "U.S. Person" (as defined in Regulation S under the 1933 Act) except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the 1933 Act and any applicable state securities laws. The Company will not be registered under the U.S. Investment Company Act of 1940, as amended (the "1940 Act") pursuant to Section 3(c)(1) of the 1940 Act. Accordingly, the Company will limit the number of beneficial owners of its shares that are "U.S. Persons" as defined in Regulation S under the 1933 Act to not more than 100, as determined in accordance with the 1940 Act and the regulations thereunder. The Shares have not been approved or disapproved by the U.S. Securities and Exchange Commission or any state securities commission, nor has any such regulatory authority passed upon or endorsed the merits of this offering or the accuracy or adequacy of this Prospectus. Any representation to the contrary is unlawful. The Directors do not intend to permit Shares of any Class of the Company acquired by investors subject to the United States Employee Retirement Income Security Act of 1974, as amended ("ERISA"), and by other benefit plan investors, as defined in ERISA, to equal or exceed 25% of the value of any such Class (determined in accordance with ERISA). Accordingly, each prospective applicant for Shares will be required to represent and warrant as to whether and to what extent he is a "benefit plan investor" for the purposes of ERISA. For additional information on investments by U.S. Persons, including certain U.S. securities law, U.S. federal tax, and ERISA and other benefit plan considerations, please see Appendix IV of the Prospectus.

Other jurisdictions

The distribution of this document of the Fund or Prospectus of the Fund and the offering of Shares of the Fund may be restricted in certain jurisdictions. This document or the Prospectus of the Fund does not constitute an offer or solicitation in any jurisdiction in which such offer or solicitation is not authorised or the person receiving the offer or solicitation may not lawfully do so. It is the responsibility of any person in possession of this document or the Prospectus of the Fund and of any person wishing to apply for Shares of the Fund to inform himself of and to observe all applicable laws and regulations of the countries of his nationality, residence, ordinary residence or domicile.